Latest News
Connected Thinking
Leading Voices
Latest News
Study: Physicians Should Prioritize Weight Management in Breast Cancer Care to Boost Survival Rates
A new study underscores the importance of weight counseling in breast cancer. Gains and losses are associated with lower chance of survival, especially in patients who undergo chemotherapy.
Learn MoreStudy Raises Clinical Considerations for Strategic Immunotherapy Use in Metastatic Cancer Care
New Yale study finds a significant rise in the use of immunotherapy in late-stage cancer, highlighting its growing use in end-of-life care and a greater success rate at larger institutions.
Learn MoreNearly 50% Skip Prescribed Breast Cancer Meds; Physicians Should Focus On Cost Cutting and Education
A new study suggests that cost-reduction policies and targeted interventions significantly increase adjuvant endocrine therapy adherence among breast cancer survivors.
Learn MoreCriteria and Considerations for Using Newly FDA-Approved Lifileucel in Advanced Melanoma
FDA grants accelerated approval for lifileucel, a TIL therapy for advanced melanoma, marking a first for a cellular therapy targeting a solid tumor.
Learn MorePhysicians Advised to Consider Rybrevant for EGFR Mutation-Positive NSCLC, Following FDA Approval
Rybrevant receives FDA approval as a game-changing treatment for NSCLC with specific genetic mutations, marking a significant advancement in personalized cancer therapy.
Learn MoreElahere Has Become A Practice-Changing Option for Platinum-Resistant, FRα Ovarian Cancer
FDA-approved Elahere for FRα-positive, platinum-resistant ovarian cancer offers new hope with its targeted mechanism and positive trial results.
Learn MoreIntegrating Venetoclax Into CLL Management Is Expanding Treatment Horizons and Improving Survival
Clinical Relevance: Venetoclax can offer your CLL patients a powerful, targeted treatment that is personalized and more effective care with fewer side effects than many other options. _________________________________________________________________________________________________________ Oncologists treating chronic lymphocytic leukemia (CLL) and select small lymphocytic lymphomas should strongly consider adding Venetoclax (Venclexta) to their arsenal, given its proven capacity to significantly enhance […]
Learn MoreBalversa’s FDA Approval Means a New, Practice-Changing Option for FGFR-Positive Bladder Cancer
Clinical Relevance: Newly FDA-approved Balversa offers a targeted treatment option for patients with FGFR3-positive metastatic bladder cancer, demonstrating significant efficacy in progression-free and overall survival rates, and should be considered post platinum-containing chemotherapy or anti-PD-(L)1 therapy failures. _________________________________________________________________________________________________ Oncologists now have a new option to consider in their decision-making process thanks to the full US […]
Learn More